Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | CPA1 | P15085 | 2/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 14/20 | 0.60 |
| ▸ | MMP1 | P03956 | 9/20 | 0.60 |
| ▸ | MMP3 | P08254 | 9/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 4/20 | 0.57 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966735 | 1.00 | MME (0.64) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL29232996 | 0.94 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL13609083 | 0.89 | MME (0.68) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL27889032 | 0.86 | MMP3 (0.76) | MMP2MMP1MMP3MMP7BIRC2 | |
| SCHEMBL13427629 | 0.85 | MME (0.65) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL18558016 | 0.84 | MMP1 (0.61) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL8583007 | 0.84 | MME (0.64) | MMEACECPA1ACE2HDAC3 | |
| SCHEMBL30973624 | 0.84 | MME (0.64) | MMEACECPA1ACE2HDAC3 | |
| SCHEMBL9956195 | 0.84 | MME (0.64) | MMEACECPA1ACE2HDAC3 | |
| SCHEMBL7787562 | 0.83 | MME (0.55) | MMEACECPA1ACE2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187579-B2 | Thickening agent | AJINOMOTO CO., INC. (JP) | 2012-05-29 | — | — | US | claimed |
| US-8187579-B2 | Thickening agent | AJINOMOTO CO., INC. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20090030092-A1 | THICKENING AGENT | AJINOMOTO CO., INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030092-A1 | THICKENING AGENT | CUTA, NAAA, ACOT7 | MME 3656/4885ACE 3884/4885CPA1 991/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | MME 1046/4885ACE 3199/4885CPA1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.